Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

Tomislav Dragovich, Christopher Campen, Tomislav Dragovich, Christopher Campen

Abstract

Cancers of the esophagus and stomach present a major health burden worldwide. In the past 30 years we have witnessed some interesting shifts in terms of epidemiology of esophago gastric cancers. Regardless of a world region, the majority of patients diagnosed with esophageal or gastric cancers die from progression or recurrence of their disease. While there are many active cytotoxic agents for esophageal and stomach cancers, their impact on the disease course has been modest at best. Median survival for patients with advanced gastroesophageal cancer is still less than a year. Therefore, novel strategies, based on our understanding of biology and genetics, are desperately needed. Epidermal growth factor receptor (EGFR) pathway has been implicated in pathophysiology of many epithelial malignancies, including esophageal and stomach cancers. EGFR inhibitors, small molecule tyrosine kinase inhibitors and monoclonal antibodies, have been explored in patients with esophageal and gastric cancers. It appears that tumors of the distal esophagus and gastroesophageal junction (GEJ) may be more sensitive to EGFR blockade than distal gastric adenocarcinomas. Investigations looking into potential molecular predictors of sensitivity to EGFR inhibitors for patients with esophageal and GEJ cancers are ongoing. While we are still searching for those predictors, it is clear that they will be different from ones identified in lung and colorectal cancers. Further development of EGFR inhibitors for esophageal and GEJ cancers should be driven by better understanding of EGFR pathway disregulation that drives cancer progression in a sensitive patient population.

Figures

Figure 1
Figure 1
A section of human gastroesophageal adenocarcinoma stained by an anti-EGFR monoclonal antibody and biotin streptavidin 3,3′-diaminobenzidine method (Courtesy of Dr. Amanda Baker, University of Arizona).

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer Journal for Clinicians. 2008;58(2):71–96.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 2001;94(2):153–156.
    1. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. Journal of Gastroenterology. 2008;43(4):256–264.
    1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Seminars in Oncology. 1999;26(5) supplement 15:2–8.
    1. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. The New England Journal of Medicine. 1999;340(11):825–831.
    1. Enzinger PC, Mayer RJ. Esophageal cancer. The New England Journal of Medicine. 2003;349(23):2241–2252.
    1. Correa P, Fox J, Fontham E, et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer. 1990;66(12):2569–2574.
    1. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clinical Cancer Research. 2007;13(19):5869–5875.
    1. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of Clinical Oncology. 2006;24(10):1612–1619.
    1. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. Journal of Clinical Oncology. 2006;24(30):4922–4927.
    1. Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent gastrointestinal malignancy: phase II efficacy and biomarker analyses. In: Proceedings of the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; 2008; abstract no. 43.
    1. Oncology drugs approved by the FDA. December 2008, .
    1. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biology & Therapy. 2006;5(4):340–342.
    1. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (VectibixTM) Oncologist. 2007;12(5):577–583.
    1. Cohen MH, Johnson JR, Chen Y-F, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist. 2005;10(7):461–466.
    1. Laurent-Puig P, Taieb J. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Current Opinion in Oncology. 2008;20(4):454–458.
    1. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Journal of the American Medical Association. 2007;298(1):70–82.
    1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. The New England Journal of Medicine. 2008;358(11):1160–1174.
    1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. 2005;5(5):341–354.
    1. Hynes NE, Lane HA. Erratum: ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. 2005;5(7):p. 580.
    1. Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study. In: Proceedings of the American Society of Clinical Oncology Annual Meeting; 2008; abstract no. 4536.
    1. Ku GY, Shah MA, Tang LH, et al. Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer. In: Proceedings of the American Society of Clinical Oncology Annual Meeting; 2008; abstract no. 15580.
    1. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Annals of Oncology. 2007;18(3):510–517.
    1. Han S-W, Oh D-Y, Im S-A, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. British Journal of Cancer. 2009;100(2):298–304.
    1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer. 2006;6(9):714–727.
    1. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of Clinical Oncology. 2000;18(4):904–914.
    1. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? The Oncologist. 2008;13(2):113–119.
    1. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. 2006;6(10):803–812.
    1. Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) pluls irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Clinical Cancer Research. 2001;7:p. 3766s. abstract no. 559.
    1. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical Cancer Research. 2007;13(13):3913–3921.
    1. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarvala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology. 2004;22(1):77–85.
    1. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer. 2005;15(5):785–792.
    1. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Journal of Clinical Oncology. 2007;25(18, supplement) abstract no. 4037.
    1. Enzinger PC, Mayer RJ. Esophageal cancer. The New England Journal of Medicine. 2003;349(23):2241–2252.
    1. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. European Journal of Cancer. 1997;33(8):1216–1220.
    1. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. Journal of Clinical Oncology. 1998;16(5):1826–1834.
    1. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer Journal. 2000;6(5):316–323.
    1. Petrasch S, Welt A, Reinacher A, Graeven U, König M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. British Journal of Cancer. 1998;78(4):511–514.
    1. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Journal of Clinical Oncology. 1999;17(10):3270–3275.
    1. Kok TC, van der Gaast A, Dees J, et al. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. British Journal of Cancer. 1996;74(6):980–984.
    1. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Seminars in Oncology. 2004;31(4):574–587.
    1. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology. 1997;15(1):261–267.
    1. van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 Study Group. Journal of Clinical Oncology. 2006;24(31):4991–4997.
    1. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008;113(5):945–955.
    1. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England Journal of Medicine. 2008;358(1):36–46.
    1. Seo M-D, Lee K-W, Lim JH, et al. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Japanese Journal of Clinical Oncology. 2008;38(9):589–595.
    1. Oh SY, Kwon H-C, Seo B-G, Kim S-H, Kim J-S, Kim H-J. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncologica. 2007;46(3):336–341.
    1. Ajani JA, Lee F-C, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology. 2006;24(4):663–667.
    1. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Research. 2006;66(8):3963–3966.
    1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–3310.
    1. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26(22):3227–3239.
    1. Takaoka M, Harada H, Andl CD, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Research. 2004;64(21):7711–7723.
    1. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. International Journal of Cancer. 1993;54(2):213–219.
    1. Rygiel AM, Milano F, Ten Kate FJ, et al. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of barrett's esophagus. Cancer Epidemiology Biomarkers & Prevention. 2008;17(6):1380–1385.
    1. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and barrett's with high-grade dysplasia. Clinical Cancer Research. 2003;9(13):4819–4825.
    1. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. European Journal of Cancer. 2001;37(supplement 4):S9–S15.
    1. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52(6):738–746.
    1. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. Journal of Clinical Oncology. 2006;24(26):4309–4316.
    1. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clinical Cancer Research. 2005;11(12):4338–4340.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir